Share & Earn


IBS Awareness Month: Diagnostic tips, treatment options, multidisciplinary care and more

0 2 years ago

According to the International Foundation for Gastrointestinal Disorders, IBS affects nearly 45 million people in the U.S. and 10% to 15% of the global population. Although common, many people remain undiagnosed and unaware that their symptoms can be managed. Further, patients are often stigmatized and misunderstood, creating a significant impact on their quality of life

While the exact pathogenesis of IBS remains largely unknown, scientific evidence points to disturbances in gut, brain and nervous system interaction that can cause changes to normal bowel function and produce symptoms ranging from mild inconvenience to severe debilitation.

In support of IBS Awareness Month, Healio has compiled eight recent reports on diagnostic tips, treatment updates, pain management and long-term care for patients with IBS.

Open-label placebo reduces pain in pediatric, adolescent functional GI disorders

Open-label placebo reduced pain and rescue medication use among pediatric and adolescent patients with functional abdominal pain and IBS, according to research published in JAMA Pediatrics.

“Although placebo responses probably play a role in virtually every clinical intervention, the use of deceptive placebos as stand-alone treatments has largely been discouraged because of ethical concerns about patient deception,” Samuel Nurko, MD, MPH, of the Center for Motility and Functional Gastrointestinal Disorders at Boston’s Children’s Hospital, and colleagues wrote. “Until recently, it has been widely believed that patient blinding (via deception or concealment) is required to elicit placebo effects, but recent studies with adults suggest that the open-label placebo honestly prescribed treatment can yield positive effects.”

Read more.

Relistor produces rescue-free laxation in patients with opioid-induced constipation

A single dose of Relistor injection produced rescue-free laxation in severely ill patients with opioid-induced constipation who had an insufficient response to laxative therapy, according to a study published in the Journal of Emergency Medicine.

“Methylnaltrexone (Relistor) works in the majority of opioid-induced constipation patients within four hours, and its use doesn’t change the analgesic effects of the opioid,” W. Frank Peacock, MD, FACEP, FACC, lead author and director of research at Baylor College of Medicine in Houston, told Healio.

Read more.

Leave a Comment

Your email address will not be published. Required fields are marked *